The community speaks

Every year, our program includes keynote speeches by some of the top thinkers and trend-makers in pharma, biotech, medtech, digital health, investment & funding, regulatory.

NLS Days features company presentations organised into tracks that interest specific audiences and fields, for example: pharma and biotechnology in R&D, therapeutics or diagnostics, academic and startup innovators, services providers.

Super Sessions address hot topics in science, business development and market strategies.

In between all of these delightful speaking events, we make sure everyone is refreshed by a classic Swedish ‘fika’ – all that your heart desires, plus lots of coffee.

Christophe Bonny

CSO - Enterome

14 Sep 11:15 Plenary Room - Main Hall Super Session 7 – Transformative Oncology

Agnete Fredriksen

Chief Scientific Officer - Vaccibody AS

13 Sep 14:00 Plenary Room - Main Hall Super Session 3 – Infectious Diseases & Vaccines

Guiseppe Ciaramella

Chief Scientific Officer - Moderna Valera Therapeutics

13 Sep 14:00 Plenary Room - Main Hall Super Session 3 – Infectious Diseases & Vaccines

Ana Maria Henao Restrepo

Medical Officer, Department of Immunization Vaccines and Biologicals - WHO

13 Sep 14:00 Plenary Room - Main Hall Super Session 3 – Infectious Diseases & Vaccines

Gary Sclar

Vice President - Dana-Farber Innovations

14 Sep 11:15 Plenary Room - Main Hall Super Session 7 – Transformative Oncology

Stephan Christgau

Partner - Novo Seeds

14 Sep 14:00 Plenary Room - Main Hall Super Session 8 – The Nordic Capital Landscape

Pontus Ottosson

Head of Investments - Chalmers Ventures

14 Sep 14:00 Plenary Room - Main Hall Super Session 8 – The Nordic Capital Landscape

Mathias Norrman

Principle Scientist - Novo Nordisk

14 Sep 11:15 Room E Workshop 4 – ESS & MAX IV

12 Sep 10:00 Bus Tour to Lund Medicon Village, Lund / Guided tour to MAX IV

Björn Walse

CEO - SARomics Biostructures

12 Sep 10:00 Bus Tour to Lund Medicon Village, Lund / Guided tour to MAX IV

Tomas Lundqvist

Life Science Director - MAX IV

12 Sep 10:00 Bus Tour to Lund Medicon Village, Lund / Guided tour to MAX IV

Sindra Petersson Årsköld

Senior Advisor - ESS

12 Sep 10:00 Bus Tour to Lund Medicon Village, Lund / Guided tour to MAX IV

Stefan Johansson

Managing Director - Invest in Skåne

12 Sep 10:00 Bus Tour to Lund Medicon Village, Lund / Guided tour to MAX IV

Pia Kinhult

Strategic Advisor - ESS

12 Sep 10:00 Bus Tour to Lund Medicon Village, Lund / Guided tour to MAX IV

Hanne B. Rasmussen

VP, Protein Structure, Interaction & Modelling - Novo Nordisk A/S

Helen Sjögren

Global Pharmaceutical R&D - Ferring Pharmaceuticals

Sara Gunnerås

Director EU Support Office - SwedenBIO

13 Sep 14:00 Room E Workshop 1 – Eurostars- Funding Opportunities for Life Science SMEs

Richard Stratford

CEO - OncoImmunity

14 Sep 11:15 Plenary Room - Main Hall Super Session 7 – Transformative Oncology

Peter Lindberg

EUROSTARS Program Manager - Vinnova

13 Sep 14:00 Room E Workshop 1 – Eurostars- Funding Opportunities for Life Science SMEs

Michael Dabrowski

CEO - Pelago Bioscience

14 Sep 08:00 Plenary Room - Main Hall Super Session 5 – Preclinical & Clinical Methodological Advancements

Michael May

CEO - Center for Commercialization of Regenerative Medicine

Karin Hehenberger

CEO and Founder - Lyfebulb

13 Sep 09:30 Plenary Room - Main Hall Super Session 1 – Diabetes

Jutta Heix

International Advisor - Oslo Cancer Cluster

Inga Bruskeland

National Project Coordinator - Research Council of Norway

13 Sep 14:00 Room E Workshop 1 – Eurostars- Funding Opportunities for Life Science SMEs

Elisabet Nielsen

EUREKA National Project Coordinator - Vinnova

13 Sep 14:00 Room E Workshop 1 – Eurostars- Funding Opportunities for Life Science SMEs

Anna Danestig

Key Account Manager - PRV

14 Sep 14:00 Plenary Room - Main Hall Super Session 8 – The Nordic Capital Landscape

Anders Hjelmencrantz

Partner and European Patent Attorney - Zacco

13 Sep 14:00 Plenary Room - Main Hall Super Session 3 – Infectious Diseases & Vaccines

Sverre Bengtsson

CEO - Pharma Consulting Group

14 Sep 08:00 Plenary Room - Main Hall Super Session 5 – Preclinical & Clinical Methodological Advancements

Sven Kili

Head of Cell & Gene Therapy Development - GSK

13 Sep 11:15 Plenary Room - Main Hall Super Session 2 – Regenerative Medicine

Steve Smith

European Patent Attorney - Potter Clarkson

13 Sep 15:45 Room E Workshop 2 – Intellectual Property

Ralf Knöll

Chief Scientist - AstraZeneca

13 Sep 11:15 Plenary Room - Main Hall Super Session 2 – Regenerative Medicine

Andy Gibbs

Drug Development Leader - Covance

14 Sep 08:00 Plenary Room - Main Hall Super Session 5 – Preclinical & Clinical Methodological Advancements

Olivier Laing

Senior Associate, IP Solicitor - Potter Clarkson

13 Sep 15:45 Room E Workshop 2 – Intellectual Property

Mats Grahn

CEO - Immunovia

13 Sep 15:45 Room E Workshop 2 – Intellectual Property

Jukka Lausmaa

Research manager, Medical technology - RISE

Bjørg Nilsson

Senior Advisor - Norwegian Institute of Public Health

Birgitte Volck

Vice President, Head of R&D Rare Diseases - GSK

13 Sep 15:45 Plenary Room - Main Hall Super Session 4 – Financing of Phase 3 Studies

Benjamin Schmid

Research Scientist, Disease Models - Bioneer

13 Sep 11:15 Plenary Room - Main Hall Super Session 2 – Regenerative Medicine

Annie Chandy

Innovation Manager - Lund University Diabetes Center

Anna Collén

Project Director Pharmaceutical Development - AstraZeneca

14 Sep 11:15 Room E Workshop 4 – ESS & MAX IV

12 Sep 10:00 Bus Tour to Lund Medicon Village, Lund / Guided tour to MAX IV

Anna Sandström

Director Science Relations - AstraZeneca

14 Sep 11:15 Room E Workshop 4 – ESS & MAX IV

Poul Henning Jensen

Professor - Dept. Of Biomedicine, Aarhus University

14 Sep 09:30 Room E Workshop 3 – Innovative Medicine Initiative

Peter Olofsson

CEO - Redoxis AB

14 Sep 09:30 Room E Workshop 3 – Innovative Medicine Initiative

Magali Poinot

Advisor and Legal Manager - IMI Joint Undertaking

14 Sep 09:30 Room E Workshop 3 – Innovative Medicine Initiative

Magda Chlebus

Director of Science Policy - EFPIA

14 Sep 09:30 Room E Workshop 3 – Innovative Medicine Initiative

Torkel Gren

Senior Sales Director, Development Services - Recipharm

14 Sep 08:00 Plenary Room - Main Hall Super Session 5 – Preclinical & Clinical Methodological Advancements

Nils Bohlin

Partner & Global Leader Healthcare - Arthur D. Little

14 Sep 15:15 Main Hall Closing Address – Nordic Stars Awards

Ben van der Schaaf

Principal - Arthur D. Little

13 Sep 15:45 Plenary Room - Main Hall Super Session 4 – Financing of Phase 3 Studies

Steffen Thirstrup

Director Regulatory Advisory Board - NDA Reg

13 Sep 11:15 Plenary Room - Main Hall Super Session 2 – Regenerative Medicine

Henrik Winther

Senior Vice President, Precision Diagnostics - Immunovia

14 Sep 11:15 Plenary Room - Main Hall Super Session 7 – Transformative Oncology

Amir Hefni

Country Manager - Bristol-Myers Squibb

14 Sep 09:30 Plenary Room - Main Hall Super Session 6 – Digital Health – New Patient Data

Marianne Larsson

Innovation Director - Innovation Skåne

14 Sep 09:30 Plenary Room - Main Hall Super Session 6 – Digital Health – New Patient Data

Christina Herder

CEO - Modus Therapeutics

14 Sep 08:00 Plenary Room - Main Hall Super Session 5 – Preclinical & Clinical Methodological Advancements

Jo Sawyer

Head of External Partnerships - Novartis

13 Sep 15:45 Plenary Room - Main Hall Super Session 4 – Financing of Phase 3 Studies

Uli Wendt

Head External Innovation and Alliance Management, Global Diabetes Division, R&D - Sanofi

13 Sep 09:30 Plenary Room - Main Hall Super Session 1 – Diabetes

Charlotte Ling

Professor Lund University

13 Sep 09:30 Plenary Room - Main Hall Super Session 1 – Diabetes

Khatereh Ahmadi

Executive Director, Oncology Search and Evaluation Lead - MSD

14 Sep 11:15 Plenary Room - Main Hall Super Session 7 – Transformative Oncology

Benedicte Bakke

Senior Advisor, International Healthcare - DNB

14 Sep 11:15 Plenary Room - Main Hall Super Session 7 – Transformative Oncology

Per Norlèn

CEO -Alligator Bioscience

14 Sep 11:15 Plenary Room - Main Hall Super Session 7 – Transformative Oncology

Stefan Ries

Global Head of External Innovation, Oncology Discovery - pRED Roche

14 Sep 11:15 Plenary Room - Main Hall Super Session 7 – Transformative Oncology

Johan Christenson

Partner - HealthCap

13 Sep 15:45 Plenary Room - Main Hall Super Session 4 – Financing of Phase 3 Studies

Ulrica Sehlstedt

Partner - Arthur D. Little

13 Sep 15:45 Plenary Room - Main Hall Super Session 4 – Financing of Phase 3 Studies

Yilmaz Mahshid

Investment Manager Life Science - Industrifonden

14 Sep 14:00 Plenary Room - Main Hall Super Session 8 – The Nordic Capital Landscape

Søren Bregenholt

Corporate VP and Head of External Innovation - Novo Nordisk

13 Sep 09:30 Plenary Room - Main Hall Super Session 1 – Diabetes

Mikael Dolsten

President Worldwide Research and Development and EVP - Pfizer

13 Sep 08:30 Plenary Room - Main Hall Opening Plenary

Jonas Ekstrand

Managing Director - SwedenBIO

14 Sep 15:15 Main Hall Closing Address – Nordic Stars Awards

13 Sep 08:30 Plenary Room - Main Hall Opening Plenary

Olivier Duchamp

Managing Director - NLSDays CEO - Bionordic Services

14 Sep 15:15 Main Hall Closing Address – Nordic Stars Awards

13 Sep 08:30 Plenary Room - Main Hall Opening Plenary